• Explore /
  • Poster
  • / Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC).

Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC).

Abstract Poster

Authors

null

Amishi Yogesh Shah

The University of Texas MD Anderson Cancer Center, Houston, TX

Amishi Yogesh Shah , Robert J. Motzer , Andrea B. Apolo , Thomas Powles , Bernard Escudier , Joshua Zhang , Christian Scheffold , Sravan Karumanchi , Linh Thuy Nguyen , Toni K. Choueiri

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT03141177

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4561)

DOI

10.1200/JCO.2021.39.15_suppl.4561

Abstract #

4561

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Andrea B. Apolo

First Author: David Cella

First Author: Jens Bedke

First Author: Viktor Grünwald